Wikipedia -WSS

Wikipedia

author：leisure time 2025-09-28 00:54:04 - browse：58455

A product image of the Cue reader COVID-19 home use test — Businesswire via AP

The Food and Drug Administration warned consumers Monday to not use Cue Health’s at-home Covid-19 tests. This follows an FDA warning letter to the company last week that said Cue was not following the conditions stipulated in the emergency use authorizations for its tests.

The FDA letters said the tests could give false results. Specifically, the agency said that the company had changed how the electrochemical signals within the test device were generated, received, and interpreted — changes the FDA has not authorized. These changes decreased the stability of the tests and might lead to false results, the agency said.

The FDA warnings come near what might be the end of a spectacularly bumpy ride for the company. When Cue went public in 2021, it was valued at nearly $3 billion. It supplied tests for the NBA’s 2020 “bubble,” leading a Trump administration official to proclaim that if the test was “good enough for LeBron,” the administration would bring it to the American people — and it did, in a $481 million deal.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The public health thinking behind the CDC’s new Covid guidance

leisure time

WSS

Fetal cell organoids grown from amniotic fluid, study finds

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Study suggests Covid rebound is far more common with Paxlovid than without

The untold story of TV’s first prescription drug ad

Families look for replacement for GSK asthma drug Flovent

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

focus

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Walensky prepares to leave CDC — and Congress — behind

What is STAT's opinion section for?

The cancer drug shortage isn’t new — and neither are the solutions

Lack of health data on LGBTQ+ people has serious consequences

Moonlake's readout produced a cash windfall. Risks remain

Carbon Health diabetes program, a test of data

Moonlake's readout produced a cash windfall. Risks remain

A letter from the executive editor: STAT UnitedHealth investigation

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How state and local governments are sidelining science

explore

NIH chief: government has fallen behind pharma on clinical trials

Longer MASH drug regimen improved liver, Akero study finds

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Medical school prerequisites are outdated

Medical school prerequisites are outdated

Change Healthcare: What is it, why does its cyberattack matter?

entertainment

leisure time

entertainment

entertainment